Autopsy report · NCT00790699

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

“Lack of patient population”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years 3 months before it stopped.
• 31 participants enrolled.
• Results were posted on the registry 8 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Texas Diabetes & Endocrinology, P.A.

Sponsor type

University, hospital or other

Conditions

Type 1 Diabetes; Type 2 Diabetes

Interventions

I-PORT; standard injections

Participants

31

Sites

1

Countries

United States

Trials that died the same way

• POLA+BR for Relapsed or Refractory DLBCL
  “Lack of sufficient patient population” (95% match in meaning)
• Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation
  “Lack of patients” (87% match in meaning)
• Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
  “patient population” (82% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (80% match in meaning)
• Ridge Preservation Comparing Simultaneous vs. Delayed Grafting
  “Not enough patients available” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.